Cytomegalovirus (CMV) expert Sallie Permar, M.D., Ph.D., of NewYork-Presbyterian/Weill Cornell Medical Center says lack of awareness and funding as well as some characteristics of the virus itself have slowed development of vaccine against CMV.
Third of four parts
Researchers have been pursuing a vaccine for cytomegalovirus (CMV) for 50 years, according to Sallie Permar, M.D., Ph.D., and vaccine pioneer Stanley Plotkin turned to CMV as the very next target after spearheading the development of the rubella vaccine.
Still there is no vaccine.
Lack of the limelight is partly the reason, said Permar, who gave a talk this afternoon at the ID Week 2023 meeting in Boston titled “CMV Vaccines: Where Are We Now?”
Polls show that only 9% of women who are of childbearing age know about CMV, said Permar. “I don't think it's gotten the attention from the public. It has not gotten the attention from the funders. It's not gotten attention even the from scientists that this is a problem they should be focused on. And I think that's held the field back,” said Permar, who is a leader in the research of prevention and treatment of neonatal viral infections and chair of the Department of Pediatrics at Weill Cornell Medicine and pediatrician-in-chief at NewYork-Presbyterian/Weill Cornell Medical Center and the NewYork-Presbyterian Komansky Children’s Hospital.
Vaccine development has also been difficult because of inherent properties of CMV, Permar explained. It has a large DNA genome and has evolved to have strategies to evade the immune system that more extensive than any other viral pathogen, she said.
CMV’s large genome has also made it versatile when it comes to entering cells, Permar explained. It has 14 different immune complexes on it surface that it uses in combinations to enter cells compared with SARS-CoV-2, the virus that causes COVID-19, which has the now-famous single spike protein.
With Its Future in Doubt, One of the Architects Makes a Case for PEPFAR | IDWeek 2023
October 15th 2023Mark Dybul, M.D., the keynote speaker for the closing session of the IDWeek meeting in Boston, delivered an impassioned defense of the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) as its reauthorization by Congress has got ensnarled in abortion issues.
Read More
Cytomegalovirus Update: For the First Time, a Phase 3 Vaccine Trial | IDWeek 2023
October 14th 2023Cytomegalovirus (CMV) expert Sallie Permar, M.D., Ph.D., of NewYork-Presbyterian/Weill Cornell Medical Center spoke about the phase 3 trial of Moderna’s mRNA vaccine against CMV and another candidate being developed by Merck that showed some promise in a phase 2B trial.
Read More
Cytomegalovirus Update: Congenital CMV Is a ‘Disease of Disparity’ | IDWeek 2023
October 14th 2023Cytomegalovirus (CMV) expert Sallie Permar, M.D., Ph.D., of NewYork-Presbyterian/Weill Cornell Medical Center says the epidemiology of congenital CMV hasn’t varied much over the years and that the condition does disproportionately affect lower socioeconomic populations and communities of color in the U.S.
Read More
Cytomegalovirus Update: ‘CMV Is Like a Zika Epidemic, Times 10, Every Year’ | IDWeek 2023
October 14th 2023Cytomegalovirus (CMV) expert Sallie Permar, M.D., Ph.D., of NewYork-Presbyterian/Weill Cornell Medical Center says that as the most common infectious cause of long-term disability CMV should be the number one target of vaccine development.
Read More